Christopher Kroeger files Form 144 to sell MPLT shares

Maplight Therapeutics, Inc. notice under Form 144 reports proposed sales of Common Stock by Christopher Kroeger.

Rhea-AI Filing Summary

Maplight Therapeutics, Inc. notice under Form 144 reports proposed sales of Common Stock by Christopher Kroeger. The filing lists a sale of 9,135 shares on 04/15/2026 for $246,020.99 and 10,052 shares on 04/16/2026 for $275,140.33. The filing also references vested RSUs dated 07/05/2024.

Key Figures

Transaction 1 - shares sold: 9,135 shares Transaction 1 - proceeds: $246,020.99 Transaction 2 - shares sold: 10,052 shares +2 more

5 metrics

Transaction 1 - shares sold 9,135 shares sale dated 04/15/2026

Transaction 1 - proceeds $246,020.99 aggregate proceeds for 04/15/2026 sale

Transaction 2 - shares sold 10,052 shares sale dated 04/16/2026

Transaction 2 - proceeds $275,140.33 aggregate proceeds for 04/16/2026 sale

Referenced vested RSUs Vested RSU dated 07/05/2024 security origin referenced in filing

Key Terms

Form 144, Vested RSU, Aggregate proceeds

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Vested RSU financial

"Common | 07/05/2024 | Vested RSU"

Aggregate proceeds financial

"04/15/2026 | 9135 | 246020.99"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the MPLT Form 144 filed for Christopher Kroeger report?

The filing reports proposed sales by Christopher Kroeger totaling two transactions: 9,135 shares on 04/15/2026 for $246,020.99 and 10,052 shares on 04/16/2026 for $275,140.33.

Does the filing show when the securities were acquired for MPLT?

The filing references vested RSUs dated 07/05/2024, indicating the origin of some securities. It does not provide additional purchase or grant-price details in the excerpt provided.

How many shares and proceeds are shown for the 04/15/2026 transaction in the MPLT filing?

The excerpt lists a sale of 9,135 shares on 04/15/2026 with aggregate proceeds of $246,020.99 for that transaction.

How many shares and proceeds are shown for the 04/16/2026 transaction in the MPLT filing?

The excerpt lists a sale of 10,052 shares on 04/16/2026 with aggregate proceeds of $275,140.33 for that transaction.

Is there evidence in the Form 144 excerpt that Maplight (MPLT) is selling shares directly?

No. The excerpt shows proposed sales by an affiliate, Christopher Kroeger, and references vested RSUs. It does not state that the issuer, Maplight Therapeutics, is selling shares on its own behalf.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 05:47 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001658918
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 CHESAPEAKE DRIVE REDWOOD CITY CALIFORNIA 94063
Phone	650-839-4360
Name of Person for Whose Account the Securities are To Be Sold	Kroeger Christopher A.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	236470	7259629.00	42000000	05/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/05/2024	Vested RSU	Maplight Therapeutics, Inc.			236470	07/05/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Kroeger 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	04/15/2026	9135	246020.99
Christopher Kroeger 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	04/16/2026	10052	275140.33

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 12/29/2025, and all representations regarding material non-public information were made as of the adoption of the plan. The securities to be sold were acquired upon the vesting of restricted stock units during the period of 07/05/2024 through 04/01/2026.
Date of Notice	05/04/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Christopher Kroeger
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)